| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Patient Reported Outcome Measures | 22 | 2024 | 799 | 3.300 |
Why?
|
| Severity of Illness Index | 63 | 2023 | 4320 | 3.270 |
Why?
|
| Psychometrics | 36 | 2024 | 937 | 2.780 |
Why?
|
| Fatigue | 41 | 2022 | 1239 | 2.640 |
Why?
|
| Quality of Life | 46 | 2024 | 4532 | 2.370 |
Why?
|
| Surveys and Questionnaires | 56 | 2024 | 5687 | 1.930 |
Why?
|
| Neoplasms | 76 | 2023 | 15193 | 1.770 |
Why?
|
| Pain | 39 | 2023 | 1658 | 1.600 |
Why?
|
| Health Status Indicators | 7 | 2014 | 224 | 1.530 |
Why?
|
| Pain Measurement | 26 | 2019 | 953 | 1.530 |
Why?
|
| Alopecia Areata | 3 | 2018 | 55 | 1.520 |
Why?
|
| Symptom Assessment | 9 | 2020 | 267 | 1.290 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 6 | 2020 | 91 | 1.160 |
Why?
|
| Brain Neoplasms | 16 | 2023 | 4849 | 1.150 |
Why?
|
| Reproducibility of Results | 51 | 2024 | 6009 | 1.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 8 | 2020 | 598 | 1.080 |
Why?
|
| Pain Management | 12 | 2020 | 668 | 0.950 |
Why?
|
| Immunotherapy | 6 | 2021 | 3341 | 0.950 |
Why?
|
| Cancer Pain | 5 | 2023 | 312 | 0.900 |
Why?
|
| Sickness Impact Profile | 12 | 2013 | 139 | 0.880 |
Why?
|
| Multiple Myeloma | 10 | 2021 | 2138 | 0.870 |
Why?
|
| Intestinal Obstruction | 2 | 2022 | 202 | 0.830 |
Why?
|
| Sleep Wake Disorders | 10 | 2019 | 348 | 0.830 |
Why?
|
| Middle Aged | 124 | 2023 | 86204 | 0.760 |
Why?
|
| Patient Outcome Assessment | 8 | 2022 | 245 | 0.750 |
Why?
|
| Self Report | 13 | 2017 | 756 | 0.740 |
Why?
|
| Exanthema | 1 | 2022 | 211 | 0.730 |
Why?
|
| Analgesics | 10 | 2012 | 390 | 0.730 |
Why?
|
| Male | 137 | 2023 | 123000 | 0.720 |
Why?
|
| Female | 146 | 2023 | 141928 | 0.700 |
Why?
|
| Lung Neoplasms | 17 | 2023 | 11538 | 0.700 |
Why?
|
| Aged | 108 | 2021 | 70117 | 0.690 |
Why?
|
| Oncologists | 1 | 2021 | 134 | 0.680 |
Why?
|
| Humans | 182 | 2024 | 261506 | 0.670 |
Why?
|
| Health Surveys | 12 | 2019 | 402 | 0.660 |
Why?
|
| Minocycline | 4 | 2021 | 182 | 0.640 |
Why?
|
| Adult | 107 | 2023 | 77950 | 0.640 |
Why?
|
| Cost of Illness | 9 | 2014 | 498 | 0.640 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2018 | 393 | 0.610 |
Why?
|
| Head and Neck Neoplasms | 11 | 2019 | 3976 | 0.600 |
Why?
|
| Health Status | 6 | 2023 | 590 | 0.560 |
Why?
|
| Aged, 80 and over | 55 | 2020 | 29902 | 0.550 |
Why?
|
| National Cancer Institute (U.S.) | 8 | 2020 | 211 | 0.550 |
Why?
|
| Antineoplastic Agents | 14 | 2021 | 14289 | 0.540 |
Why?
|
| Factor Analysis, Statistical | 12 | 2022 | 356 | 0.530 |
Why?
|
| Chemoradiotherapy | 7 | 2019 | 1946 | 0.520 |
Why?
|
| Glioma | 3 | 2021 | 1963 | 0.500 |
Why?
|
| Radiation Injuries | 6 | 2021 | 1411 | 0.480 |
Why?
|
| Spinal Fractures | 2 | 2012 | 132 | 0.480 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 406 | 0.470 |
Why?
|
| Cross-Sectional Studies | 21 | 2023 | 4314 | 0.460 |
Why?
|
| Virtual Reality Exposure Therapy | 2 | 2023 | 7 | 0.460 |
Why?
|
| Terminology as Topic | 6 | 2017 | 414 | 0.450 |
Why?
|
| Young Adult | 31 | 2021 | 21445 | 0.430 |
Why?
|
| Pain, Postoperative | 4 | 2011 | 610 | 0.390 |
Why?
|
| Pneumonia | 3 | 2023 | 751 | 0.390 |
Why?
|
| Translations | 4 | 2019 | 39 | 0.370 |
Why?
|
| Cognition Disorders | 2 | 2013 | 786 | 0.370 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 901 | 0.360 |
Why?
|
| Cluster Analysis | 6 | 2018 | 1053 | 0.350 |
Why?
|
| Activities of Daily Living | 5 | 2017 | 552 | 0.340 |
Why?
|
| Registries | 2 | 2013 | 2170 | 0.340 |
Why?
|
| Caregivers | 2 | 2012 | 677 | 0.340 |
Why?
|
| Prospective Studies | 19 | 2023 | 12873 | 0.330 |
Why?
|
| Stress, Psychological | 4 | 2014 | 1000 | 0.330 |
Why?
|
| Pain, Intractable | 4 | 2020 | 171 | 0.330 |
Why?
|
| Chronic Pain | 3 | 2023 | 238 | 0.320 |
Why?
|
| Esophagitis | 2 | 2021 | 202 | 0.310 |
Why?
|
| United States | 24 | 2021 | 15433 | 0.300 |
Why?
|
| Translating | 5 | 2017 | 45 | 0.290 |
Why?
|
| Adolescent | 28 | 2021 | 31252 | 0.280 |
Why?
|
| Ependymoma | 2 | 2021 | 242 | 0.270 |
Why?
|
| Longitudinal Studies | 7 | 2022 | 1945 | 0.260 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2021 | 142 | 0.260 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 5319 | 0.260 |
Why?
|
| Postoperative Period | 2 | 2004 | 665 | 0.260 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2023 | 502 | 0.260 |
Why?
|
| Breast Neoplasms | 7 | 2023 | 15694 | 0.250 |
Why?
|
| Palliative Care | 8 | 2022 | 2037 | 0.250 |
Why?
|
| Synaptic Potentials | 1 | 2014 | 16 | 0.250 |
Why?
|
| Vibrissae | 1 | 2014 | 17 | 0.250 |
Why?
|
| Osteoarthritis | 1 | 2005 | 94 | 0.250 |
Why?
|
| Survivorship | 2 | 2023 | 109 | 0.250 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 3719 | 0.230 |
Why?
|
| Inflammation Mediators | 3 | 2014 | 423 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2013 | 1303 | 0.230 |
Why?
|
| Prevalence | 12 | 2020 | 3260 | 0.230 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 1258 | 0.230 |
Why?
|
| Ghrelin | 1 | 2023 | 79 | 0.230 |
Why?
|
| Mental Recall | 2 | 2017 | 171 | 0.220 |
Why?
|
| Sensitivity and Specificity | 8 | 2017 | 4971 | 0.220 |
Why?
|
| Organoplatinum Compounds | 2 | 2016 | 702 | 0.220 |
Why?
|
| Anxiety | 5 | 2023 | 1179 | 0.220 |
Why?
|
| Language | 7 | 2012 | 309 | 0.220 |
Why?
|
| Time Factors | 14 | 2021 | 12926 | 0.210 |
Why?
|
| Kyphoplasty | 2 | 2012 | 9 | 0.210 |
Why?
|
| Vertebroplasty | 2 | 2012 | 24 | 0.210 |
Why?
|
| Depression | 7 | 2020 | 1715 | 0.200 |
Why?
|
| Fractures, Compression | 2 | 2012 | 42 | 0.200 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 199 | 0.200 |
Why?
|
| Radiotherapy | 5 | 2017 | 1824 | 0.200 |
Why?
|
| Fertility Preservation | 1 | 2023 | 150 | 0.190 |
Why?
|
| Karnofsky Performance Status | 5 | 2012 | 175 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 224 | 0.190 |
Why?
|
| Xerostomia | 3 | 2017 | 190 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 521 | 0.190 |
Why?
|
| Double-Blind Method | 7 | 2021 | 2588 | 0.180 |
Why?
|
| Prognosis | 9 | 2022 | 21713 | 0.180 |
Why?
|
| Dacarbazine | 3 | 2021 | 485 | 0.180 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 621 | 0.180 |
Why?
|
| Synapses | 1 | 2014 | 509 | 0.180 |
Why?
|
| Cordotomy | 1 | 2020 | 46 | 0.180 |
Why?
|
| Medically Underserved Area | 3 | 2011 | 101 | 0.180 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 5767 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 10035 | 0.170 |
Why?
|
| Glutamine | 1 | 2021 | 299 | 0.170 |
Why?
|
| Retrospective Studies | 15 | 2023 | 37905 | 0.170 |
Why?
|
| Radiodermatitis | 1 | 2019 | 75 | 0.170 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 394 | 0.170 |
Why?
|
| Body Image | 1 | 2020 | 141 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2018 | 9244 | 0.160 |
Why?
|
| Diarrhea | 1 | 2022 | 686 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 64 | 0.160 |
Why?
|
| Survivors | 6 | 2023 | 1031 | 0.160 |
Why?
|
| Astrocytoma | 1 | 2021 | 321 | 0.160 |
Why?
|
| Health Services Accessibility | 4 | 2011 | 761 | 0.160 |
Why?
|
| Sex Factors | 5 | 2019 | 2139 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2021 | 556 | 0.160 |
Why?
|
| Treatment Outcome | 22 | 2020 | 32848 | 0.160 |
Why?
|
| Socioeconomic Factors | 8 | 2019 | 1225 | 0.160 |
Why?
|
| Risk Assessment | 8 | 2014 | 6869 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2016 | 600 | 0.160 |
Why?
|
| Philippines | 4 | 2015 | 39 | 0.160 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2017 | 1105 | 0.160 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 3578 | 0.160 |
Why?
|
| Attitude of Health Personnel | 4 | 2011 | 918 | 0.150 |
Why?
|
| Thoracic Neoplasms | 1 | 2021 | 337 | 0.150 |
Why?
|
| Statistics, Nonparametric | 2 | 2021 | 980 | 0.150 |
Why?
|
| Age Factors | 4 | 2019 | 5377 | 0.150 |
Why?
|
| Bortezomib | 2 | 2018 | 543 | 0.150 |
Why?
|
| Texas | 6 | 2020 | 6311 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 15862 | 0.150 |
Why?
|
| Cancer Survivors | 2 | 2021 | 650 | 0.150 |
Why?
|
| Residence Characteristics | 4 | 2010 | 348 | 0.150 |
Why?
|
| Microcomputers | 1 | 2017 | 36 | 0.150 |
Why?
|
| Musculoskeletal Pain | 1 | 2017 | 21 | 0.150 |
Why?
|
| Mass Screening | 3 | 2021 | 1509 | 0.140 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 4892 | 0.140 |
Why?
|
| Paresthesia | 1 | 2016 | 33 | 0.140 |
Why?
|
| Linguistics | 1 | 2016 | 25 | 0.140 |
Why?
|
| Neurology | 1 | 2018 | 113 | 0.140 |
Why?
|
| Risk Factors | 14 | 2023 | 17523 | 0.140 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 860 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2012 | 598 | 0.140 |
Why?
|
| Touch | 1 | 2016 | 71 | 0.130 |
Why?
|
| Analysis of Variance | 4 | 2010 | 2307 | 0.130 |
Why?
|
| Terminal Care | 3 | 2011 | 447 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 622 | 0.130 |
Why?
|
| Tonsillar Neoplasms | 1 | 2015 | 80 | 0.130 |
Why?
|
| Mood Disorders | 1 | 2016 | 163 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1763 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2011 | 252 | 0.130 |
Why?
|
| Inflammation | 2 | 2014 | 2522 | 0.120 |
Why?
|
| Neoplasm Staging | 8 | 2019 | 13658 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 276 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 402 | 0.120 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 14889 | 0.120 |
Why?
|
| Hospitals, Public | 2 | 2011 | 64 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2015 | 6550 | 0.120 |
Why?
|
| Transplantation, Autologous | 2 | 2015 | 1914 | 0.120 |
Why?
|
| Amyloidosis | 1 | 2015 | 176 | 0.110 |
Why?
|
| Deglutition Disorders | 5 | 2019 | 447 | 0.110 |
Why?
|
| Dyspnea | 4 | 2022 | 416 | 0.110 |
Why?
|
| Hypesthesia | 1 | 2013 | 22 | 0.110 |
Why?
|
| Methylphenidate | 1 | 2014 | 103 | 0.110 |
Why?
|
| Interview, Psychological | 1 | 2013 | 98 | 0.110 |
Why?
|
| Mesothelioma | 1 | 2018 | 544 | 0.110 |
Why?
|
| Professional Practice | 1 | 2013 | 82 | 0.110 |
Why?
|
| Thalassemia | 1 | 2012 | 26 | 0.110 |
Why?
|
| Korea | 6 | 2010 | 63 | 0.110 |
Why?
|
| Employment | 1 | 2013 | 129 | 0.110 |
Why?
|
| Japan | 5 | 2020 | 227 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2017 | 667 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 1249 | 0.110 |
Why?
|
| Checklist | 1 | 2013 | 122 | 0.110 |
Why?
|
| Photons | 1 | 2016 | 507 | 0.110 |
Why?
|
| Cultural Characteristics | 2 | 2010 | 70 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 482 | 0.100 |
Why?
|
| Nomograms | 1 | 2014 | 313 | 0.100 |
Why?
|
| Breast Neoplasms, Male | 1 | 2013 | 229 | 0.100 |
Why?
|
| Feasibility Studies | 3 | 2023 | 2292 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2018 | 1423 | 0.100 |
Why?
|
| Glioblastoma | 2 | 2013 | 1797 | 0.100 |
Why?
|
| Pharyngitis | 1 | 2011 | 41 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 3251 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 4298 | 0.100 |
Why?
|
| Carcinoma | 1 | 2022 | 2578 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1742 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 2278 | 0.090 |
Why?
|
| Comorbidity | 4 | 2011 | 2352 | 0.090 |
Why?
|
| Terminally Ill | 1 | 2011 | 91 | 0.090 |
Why?
|
| Mucositis | 2 | 2008 | 148 | 0.090 |
Why?
|
| Reminder Systems | 1 | 2011 | 83 | 0.090 |
Why?
|
| Fluid Therapy | 1 | 2011 | 182 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 588 | 0.090 |
Why?
|
| Parenteral Nutrition | 1 | 2011 | 207 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2006 | 915 | 0.090 |
Why?
|
| Constipation | 1 | 2011 | 177 | 0.090 |
Why?
|
| Lung | 1 | 2021 | 3151 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1870 | 0.090 |
Why?
|
| Family | 1 | 2013 | 736 | 0.090 |
Why?
|
| Thoracotomy | 1 | 2011 | 220 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 1183 | 0.090 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2023 | 406 | 0.080 |
Why?
|
| Telemedicine | 2 | 2015 | 471 | 0.080 |
Why?
|
| Cancer Care Facilities | 5 | 2014 | 884 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2013 | 785 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 2231 | 0.080 |
Why?
|
| Greece | 2 | 2008 | 22 | 0.080 |
Why?
|
| Incidence | 4 | 2023 | 5673 | 0.080 |
Why?
|
| Nursing Audit | 1 | 2008 | 3 | 0.080 |
Why?
|
| Algorithms | 3 | 2020 | 3890 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 2104 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 672 | 0.080 |
Why?
|
| Personality Inventory | 1 | 2008 | 178 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 4988 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2011 | 1819 | 0.080 |
Why?
|
| Argon | 1 | 2007 | 5 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2992 | 0.070 |
Why?
|
| Tape Recording | 1 | 2006 | 14 | 0.070 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2007 | 52 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2019 | 700 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 2238 | 0.070 |
Why?
|
| Outpatients | 2 | 2012 | 462 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2011 | 661 | 0.070 |
Why?
|
| Data Collection | 2 | 2007 | 620 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 543 | 0.070 |
Why?
|
| Laser Coagulation | 1 | 2007 | 136 | 0.070 |
Why?
|
| China | 5 | 2010 | 606 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2016 | 1577 | 0.070 |
Why?
|
| Biomarkers | 4 | 2021 | 5047 | 0.070 |
Why?
|
| Urban Population | 1 | 2006 | 269 | 0.070 |
Why?
|
| Computers, Handheld | 2 | 2016 | 69 | 0.070 |
Why?
|
| Recurrence | 2 | 2011 | 4758 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6207 | 0.060 |
Why?
|
| Propensity Score | 2 | 2022 | 750 | 0.060 |
Why?
|
| Disease Progression | 3 | 2011 | 6682 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2021 | 1021 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 4367 | 0.060 |
Why?
|
| Social Values | 1 | 2004 | 62 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2023 | 665 | 0.060 |
Why?
|
| Anesthesia, Epidural | 1 | 2004 | 31 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 200 | 0.060 |
Why?
|
| Public Opinion | 1 | 2004 | 83 | 0.060 |
Why?
|
| Russia | 3 | 2010 | 54 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2004 | 81 | 0.060 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 1371 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2017 | 497 | 0.060 |
Why?
|
| Immunologic Factors | 2 | 2017 | 649 | 0.060 |
Why?
|
| Narcotics | 1 | 2004 | 123 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 1559 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 2594 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 460 | 0.060 |
Why?
|
| Fentanyl | 1 | 2004 | 148 | 0.060 |
Why?
|
| Interdisciplinary Communication | 2 | 2018 | 280 | 0.060 |
Why?
|
| Florida | 1 | 2022 | 113 | 0.050 |
Why?
|
| Anemia | 1 | 2008 | 689 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 4549 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 435 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2008 | 674 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 5061 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 6915 | 0.050 |
Why?
|
| Survival Rate | 1 | 2015 | 12221 | 0.050 |
Why?
|
| Sleep Stages | 2 | 2014 | 78 | 0.050 |
Why?
|
| Affect | 1 | 2003 | 288 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2006 | 1209 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 2527 | 0.050 |
Why?
|
| Anorexia | 2 | 2014 | 143 | 0.050 |
Why?
|
| Gastrostomy | 1 | 2022 | 180 | 0.050 |
Why?
|
| Goals | 1 | 2022 | 185 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2023 | 329 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 8865 | 0.050 |
Why?
|
| Attitude to Health | 3 | 2011 | 465 | 0.050 |
Why?
|
| Biodiversity | 1 | 2021 | 91 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2010 | 6100 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 1202 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 218 | 0.050 |
Why?
|
| Cytokines | 2 | 2014 | 2809 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2023 | 451 | 0.050 |
Why?
|
| Sleep | 1 | 2003 | 413 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 10001 | 0.050 |
Why?
|
| Jordan | 1 | 2019 | 24 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 1972 | 0.050 |
Why?
|
| Arabs | 1 | 2019 | 38 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2002 | 244 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2023 | 543 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 53 | 0.040 |
Why?
|
| Logistic Models | 3 | 2014 | 3441 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 748 | 0.040 |
Why?
|
| Latin America | 2 | 2011 | 115 | 0.040 |
Why?
|
| Morbidity | 1 | 2021 | 397 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 5437 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2019 | 57 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 256 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 708 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2003 | 557 | 0.040 |
Why?
|
| Research Design | 2 | 2018 | 1544 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 826 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2020 | 255 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 134 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2018 | 183 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 717 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 1866 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 1290 | 0.040 |
Why?
|
| Interleukin-10 | 2 | 2014 | 478 | 0.040 |
Why?
|
| Apitherapy | 1 | 2017 | 1 | 0.040 |
Why?
|
| Honey | 1 | 2017 | 4 | 0.040 |
Why?
|
| Iran | 1 | 2017 | 68 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 666 | 0.040 |
Why?
|
| Time | 1 | 2017 | 178 | 0.040 |
Why?
|
| Turkey | 1 | 2017 | 57 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 678 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 4638 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2012 | 764 | 0.040 |
Why?
|
| Indonesia | 1 | 2016 | 17 | 0.040 |
Why?
|
| Comprehension | 1 | 2017 | 120 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 48 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2004 | 1996 | 0.040 |
Why?
|
| Taiwan | 2 | 2007 | 93 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 1274 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 604 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 323 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 332 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 611 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 313 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 1183 | 0.030 |
Why?
|
| Length of Stay | 1 | 2022 | 1900 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2014 | 1038 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 1546 | 0.030 |
Why?
|
| Israel | 2 | 2005 | 53 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 1039 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2011 | 5542 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2004 | 1823 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 3472 | 0.030 |
Why?
|
| Cognition | 2 | 2013 | 968 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 1538 | 0.030 |
Why?
|
| Taxoids | 1 | 2018 | 967 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 151 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2022 | 1589 | 0.030 |
Why?
|
| Heart Failure | 1 | 2008 | 2516 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 544 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 2576 | 0.030 |
Why?
|
| Pediatrics | 1 | 2003 | 1141 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2011 | 739 | 0.030 |
Why?
|
| Decision Making | 1 | 2021 | 1287 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2014 | 209 | 0.030 |
Why?
|
| Internationality | 1 | 2014 | 208 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2013 | 29 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 208 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 300 | 0.030 |
Why?
|
| alpha-Thalassemia | 1 | 2012 | 11 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 2518 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2015 | 167 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2013 | 68 | 0.030 |
Why?
|
| Leukemia | 1 | 2002 | 1635 | 0.030 |
Why?
|
| Iron Chelating Agents | 1 | 2012 | 33 | 0.030 |
Why?
|
| Stomatitis | 1 | 2014 | 183 | 0.030 |
Why?
|
| Iron Overload | 1 | 2012 | 35 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 437 | 0.030 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2012 | 84 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 684 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2012 | 102 | 0.030 |
Why?
|
| Fractures, Spontaneous | 1 | 2012 | 84 | 0.030 |
Why?
|
| Fluorouracil | 2 | 2009 | 1944 | 0.030 |
Why?
|
| Internet | 1 | 2017 | 706 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 225 | 0.030 |
Why?
|
| Culture | 1 | 2012 | 100 | 0.030 |
Why?
|
| Psychological Tests | 2 | 2007 | 131 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 471 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2015 | 554 | 0.020 |
Why?
|
| Morocco | 1 | 2010 | 5 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2803 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2011 | 53 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 360 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2012 | 477 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 669 | 0.020 |
Why?
|
| Telephone | 1 | 2011 | 163 | 0.020 |
Why?
|
| Minority Groups | 1 | 2012 | 322 | 0.020 |
Why?
|
| Iron | 1 | 2012 | 376 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 2218 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 176 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 1178 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 5539 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 1910 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 26 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3203 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 332 | 0.020 |
Why?
|
| Patient Selection | 2 | 2008 | 2055 | 0.020 |
Why?
|
| Stem Cells | 1 | 2015 | 1213 | 0.020 |
Why?
|
| Cuba | 1 | 2008 | 10 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2008 | 96 | 0.020 |
Why?
|
| Peru | 1 | 2008 | 52 | 0.020 |
Why?
|
| Hospitals, Private | 1 | 2008 | 23 | 0.020 |
Why?
|
| Argentina | 1 | 2008 | 72 | 0.020 |
Why?
|
| Taste Disorders | 1 | 2007 | 17 | 0.020 |
Why?
|
| Mastication | 1 | 2007 | 19 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2007 | 15 | 0.020 |
Why?
|
| Capecitabine | 1 | 2009 | 388 | 0.020 |
Why?
|
| Brazil | 1 | 2008 | 165 | 0.020 |
Why?
|
| Hematinics | 1 | 2008 | 109 | 0.020 |
Why?
|
| Voice Disorders | 1 | 2007 | 39 | 0.020 |
Why?
|
| Mexico | 1 | 2008 | 259 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2012 | 621 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2008 | 205 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 4109 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 2316 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 59536 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2006 | 495 | 0.020 |
Why?
|
| Age Distribution | 1 | 2006 | 698 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2004 | 60 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2004 | 101 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 3981 | 0.020 |
Why?
|
| Cultural Diversity | 1 | 2005 | 76 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 7551 | 0.020 |
Why?
|
| Spirituality | 1 | 2005 | 129 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2004 | 257 | 0.010 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2004 | 68 | 0.010 |
Why?
|
| Arthritis | 1 | 2004 | 139 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2005 | 445 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2005 | 126 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 216 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 156 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2009 | 1353 | 0.010 |
Why?
|
| Europe | 1 | 2005 | 649 | 0.010 |
Why?
|
| Germany | 1 | 2003 | 111 | 0.010 |
Why?
|
| Norway | 1 | 2002 | 30 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 1299 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 461 | 0.010 |
Why?
|
| Remission Induction | 1 | 2009 | 3569 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 253 | 0.010 |
Why?
|
| Morphine | 1 | 2004 | 308 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2003 | 430 | 0.010 |
Why?
|
| Nausea | 1 | 2004 | 525 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 519 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2002 | 257 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 2638 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 2403 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2004 | 1544 | 0.010 |
Why?
|
| HIV Infections | 1 | 2010 | 2134 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 1529 | 0.010 |
Why?
|
| Child | 2 | 2012 | 29154 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 3001 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 2422 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2004 | 3005 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 4975 | 0.010 |
Why?
|
| Italy | 1 | 1996 | 236 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 418 | 0.010 |
Why?
|
| France | 1 | 1995 | 108 | 0.010 |
Why?
|